Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Operating Officer | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2036-08-02 | Direct | 15,000 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date. F2: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
F2: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:27 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001745566-26-000010 · ownership.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-08-02 F1 · derivative.exercise_date: The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date. F2 · balance_after: The initial Form 3 filed on August 5, 2026 was erroneously filed. This Form 4 replaces the Form 3 filed. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 00:51 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 27 | $1.30 | $35.10 |
DisclosureSEC source: 0001745566-26-000006 · ownership.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 27 shares of common stock in connection with shares that vested on June 3, 2026, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 27 shares of common stock in connection with shares that vested on June 3, 2026, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 21:26 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 20 | $1.10 | $22.00 |
DisclosureSEC source: 0001745566-26-000004 · ownership.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 895 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 20 shares of common stock in connection with shares that vested on February 15, 2026 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:17 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 27,737 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001745566-26-000002 · ownership.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,737 Underlying: Common Stock · 27,737 shares Expires 2036-02-01 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 20:49 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 59 | $4.06 | $239.54 |
DisclosureSEC source: 0001745566-25-000005 · wk-form4_1757710167.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915 F1 · kind: The reporting person is reporting the withholding by the Issuer an aggregate of 59 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer an aggregate of 59 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| September 11, 2025 Filed Sep 12, 2025 21:02 UTC Amendment | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 59 | $4.06 | $239.54 |
DisclosureSEC source: 0001745566-25-000007 · wk-form4a_1757710939.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915 F1 · kind: The reporting person is reporting the withholding by the Issuer an aggregate of 59 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer an aggregate of 59 shares of common stock that vested on September 11, 2025, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 22:59 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 27 | $3.69 | $99.63 |
DisclosureSEC source: 0001411690-25-000056 · wk-form4_1748991535.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 974 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 27 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 27 shares of common stock in connection with shares that vested on June 3, 2025, pursuant to an RSU award granted on June 3, 2024, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 22:45 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 6,966 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001411690-25-000027 · wk-form4_1742337920.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,966 Underlying: Common Stock · 6,966 shares Expires 2035-03-13 F1 · derivative.exercise_date: Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 23:57 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 20 | $5.73 | $114.60 |
DisclosureSEC source: 0001411690-25-000019 · wk-form4_1740009430.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,001 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 20 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 20 shares of common stock in connection with shares that vested on February 15, 2025 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On January 24, 2025, the common stock of Bionano Genomics, Inc. split 1-for-60, resulting in the reporting person's ownership of 60,262 less shares of common stock. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 20:15 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 3,568 | $0.48 | $1,712.64 |
DisclosureSEC source: 0001411690-24-000053 · wk-form4_1726258505.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,283 F1 · kind: The reporting person is reporting the withholding by the Issuer an aggregate of 3,568 shares of common stock that vested on September 11, 2024, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer an aggregate of 3,568 shares of common stock that vested on September 11, 2024, pursuant to an RSU award granted on September 11, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: Includes 153 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:49 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-24-015624 · form4-06052024_090633.xml · derivative · entry 2 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-06-02 F4 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of June 3, 2024 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 21:49 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015624 · form4-06052024_090633.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,698 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · shares: The shares subject to the RSUs vest 1/4th annually beginning on the one-year anniversary of the grant date. F3 · balance_after: Includes 54 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 9, 2023. Read SEC document |
| February 15, 2024 Filed Mar 5, 2024 22:47 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 1,229 | $1.27 | $1,560.83 |
DisclosureSEC source: 0001415889-24-006810 · form4-03052024_100327.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,644 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,229 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F1 · shares: The reporting person is reporting the withholding by the Issuer of an aggregate of 1,229 shares of common stock in connection with shares that vested on February 15, 2024 pursuant to an RSU award granted on February 15, 2023, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: On August 4, 2023, the common stock of Bionano Genomics, Inc. split 1-for-10, resulting in the reporting person's ownership of 268,058 less shares of common stock. F3 · balance_after: Includes 89 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan on June 12, 2023. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 21:38 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050186 · doc4.xml · derivative · entry 2 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-09-17 F2 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of September 11, 2023 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 21:38 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050186 · doc4.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 317,842 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. Read SEC document |
| May 12, 2023 Filed May 16, 2023 22:20 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 41,496 | $0.66 | $27,387.36 |
DisclosureSEC source: 0001411690-23-000030 · wf-form4_168427559071904.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,842 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 41,496 shares of common stock that vested on May 12, 2023 pursuant to an RSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-010920 · doc4.xml · derivative · entry 2 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010920 · doc4.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,338 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 1,424 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 1,245 shares acquired under the ESPP on December 10, 2022. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:27 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Tax withholdingCommon Stock | 41,496 | $1.41 | $58,509.36 |
DisclosureSEC source: 0001209191-22-029458 · doc4.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,669 F1 · kind: The reporting person is reporting the withholding by the Issuer of an aggregate of 41,496 shares of common stock that vested on May 12, 2022 pursuant to an RSU award granted on May 12, 2021, but that were not issued in order to satisfy the reporting person's tax withholding obligations upon settlement of the RSU award. F2 · balance_after: Includes 3,139 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2021 and 2,940 shares acquired under the ESPP on December 10, 2021. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 02:06 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010048 · doc4.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 23:15 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032932 · doc4.xml · nonDerivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,086 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes: 495 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on December 10, 2018, 1,021 shares acquired under the ESPP on June 10, 2019, 1,405 shares acquired under the ESPP on December 10, 2019, 1,199 shares acquired under the ESPP on June 10, 2020 and 1,151 shares acquired under the ESPP on December 10, 2020. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024788 · doc4.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 00:24 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-20-011298 · doc4.xml · derivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-02-17 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 18, 2020 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| March 01, 2019 Filed Mar 6, 2020 19:07 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016871 · doc4.xml · derivative · entry 1 OLDAKOWSKI MARK · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 02:08 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001209191-19-004894 · doc4.xml · derivative · entry 2 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,219 Underlying: Common Stock · 6,000 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on February 7, 2017, and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 02:08 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionCommon Stock | 6,000 | $1.30 | $7,800.00 |
DisclosureSEC source: 0001209191-19-004894 · doc4.xml · nonDerivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:48 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 59,590 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053866 · doc4.xml · derivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,590 Underlying: Common Stock · 59,590 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:52 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 815 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0001209191-18-048558 · doc4.xml · derivative · entry 2 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815 Underlying: Common Stock · 815 shares Expires 2023-08-21 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. F2 · derivative.exercise_date: 9/21/18 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 22:52 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 815 | $6.13 | $4,991.88 |
DisclosureSEC source: 0001209191-18-048558 · doc4.xml · nonDerivative · entry 1 Borodkin Mark · CIK 0001745566 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815 F1 · price: Units purchased in the Issuer's Initial Public Offering for $6.125 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.